EVG.L Share News (EVG)

EVG.L Information

There is currently no data for EVG

FTSE 250 movers: CSR jumps as chip sales impress

Thu, 29th Oct 2009 12:11

CSR, which makes chips for Bluetooth and Global Positioning System (GPS) devices, is sharply higher after third quarter results were better than expected.Pre-tax profits for the period totalled $10.7m compared with a $30.8m over the same period the previous year. Revenues climbed to $219.9m from $205.5m. Bluetooth accounted for $150.4m, GPS for $59.5m.At the time of its second quarter results, CSR issued third quarter guidance of $195m to $215m for revenue. The median forecast of investment analysts' revenue forecasts was $208m.Qinetiq climbs after saying the boss of defence technology group QinetiQ, Graham Love, is being replaced by the former chief of banknote printer De La Rue, Leo Quinn, after eight years at the company.Investment management firm Evolution Group is going well after saying it expects to beat full year profit forecasts this year on the back of strong trading across all of its divisions. Revenues from the Investment Banking arm in the second half of 2009 will be at least double those seen in the first half, reflecting the increased corporate activity.Elsewhere in finance, Fund manager Henderson said assets under management increased 9% to £57.7bn in the third quarter to 30 September 2009 as market conditions continue to improve.National Express is sharply lower after the hard-up bus and train group said it has ended all takeover discussions with rival Stagecoach in order to focus on completing an equity fundraising by the end of this year.Shares in Yell fall back after the cash-strapped Yellow Pages directory publisher Yell Group again extended the deadline for its refinancing. The company, which is looking to restructure £3.8bn of debt, extended the deadline for the third time this week after last night's cut-off passed without success.FTSE 250 - RisersCSR (CSR) 446.60p +11.07%QinetiQ Group (QQ.) 154.80p +8.33%Taylor Wimpey (TW.) 37.77p +5.77%Aquarius Platinum Ltd. (AQP) 274.00p +5.71%Redrow (RDW) 139.80p +5.43%Evolution Group (EVG) 158.50p +4.55%Victrex (VCT) 784.50p +4.32%Barratt Developments (BDEV) 135.30p +4.24%BlueBay Asset Management (BBAY) 368.40p +3.98%Tomkins (TOMK) 162.60p +3.90%FTSE 250 - FallersNational Express Group (NEX) 328.10p -10.01%Laird (LRD) 163.20p -9.33%PartyGaming (PRTY) 221.50p -5.54%Henderson Group (HGG) 127.40p -4.64%PayPoint (PAY) 448.50p -4.17%Melrose Resources (MRS) 357.60p -2.85%Yell Group (YELL) 45.04p -2.81%Imagination Technologies (IMG) 202.50p -2.64%Debenhams (DEB) 77.50p -2.52%PV Crystalox Solar (PVCS) 65.55p -2.16%

More News

27 Jul 2018 13:14

Friday broker round-up

(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.

26 Jul 2018 12:54

Evgen Pharma Expects Final Results From Clinical Trials At End Of Year

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug development company said at its annual

25 Jul 2018 14:48

Evgen concludes patient recruitment in STEM breast cancer trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.

25 Jul 2018 13:57

Wednesday broker round-up

(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.

25 Jul 2018 13:31

Evgen Pharma Metastatic Breast Cancer Trial Ends Patient Recruitment

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.Following the favourable

19 Jul 2018 16:21

UK Shareholder Meetings Calendar - Next 7 Days

Friday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24

13 Jun 2018 10:46

Evgen Pharma Annual Loss Narrows As It Continues Phase II Trials

LONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, which focuses on cancer and neurological

11 Jun 2018 11:33

Evgen STEM Interim Trial Result Show "Signs Of Anti-Tumour Activity"

LONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is the company's study of in a

2 May 2018 11:15

Evgen Pharma Gets European Patent For Sulforaphane Stablising Method

LONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane,

20 Mar 2018 13:56

Evgen Pharma Begins Research Partnership With Imperial College London

LONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on SFX-01, the company's

13 Feb 2017 08:21

Evgen Pharma signs service agreement with drug development corsortium

(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product. APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda

17 Jan 2017 12:35

Richard Moulson to join Evgen Pharma as CFO

(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday. The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 Febru

11 Jan 2017 09:23

Evgen Pharma receives go ahead for haemorrhage drug trial

(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial

11 Jan 2017 09:17

Evgen Pharma Gets Positive Review For SFX-01 Phase II Study

17 Aug 2016 10:49

Evgen Pharma receives approval for breast cancer study

(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w

Latest Share Chat

EVG.L Share News (EVG)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 250 movers: CSR jumps as chip sales impress

Login to your account

Quickpicks are a member only feature

Login to your account